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Abstract: Purpose: Prader Willi syndrome (PWS) is a rare genetic condition that has concurrent
endocrinological insufficiencies. The presence of growth hormone deficiency has been well
documented, but adrenal insufficiency (AI) is not widely reported. A review was conducted to
investigate its prevalence and relevance in PWS in both adults and children. Methodology: A
literature review was performed with the search terms “Prader-Willi syndrome” and “adrenal
insufficiency”. Results: The review found studies disagree on the prevalence and method of
investigation of AI in PWS. Case studies demonstrate that patients with PWS are at risk of premature
death, often secondary to respiratory infections. The possibility that this may be the result of the
inability to mount an effective cortisol response has been studied, with some evidence confirming AI
in PWS patients. Most reports agreed AI is present in PWS, however, Farholt et al. showed no HPA
axis dysfunction in adults, suggesting that perhaps it is rare in adults, and children should be the
focus of further studies. Conclusion: AI is present in some patients with PWS. Further research is
required to ensure optimal treatment can be implemented and to prevent premature deaths related
to adrenal insufficiency. Clinicians should have a low threshold for testing the adrenal axis and
considering treatment for adrenal insufficiency in PWS patients.
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1. Introduction
Prader Willi syndrome (PWS) was first described in 1956 [1]. It is a genetic condition, usually
secondary to a deletion of a segment of the paternally-inherited chromosome 15q11-q13, although
other genetic abnormalities have been described, including maternal uniparental disomy of the same
chromosome [2]. PWS is rare with a UK prevalence estimated to be around 1:52,000 and a birth
incidence of approximately 1:29,000 [3]. The prevalence appears to be rising but this could be due to
increasing awareness of the syndrome and increased diagnosis in paediatric care [4].
The different manifestations of PWS vary with age, but not gender [5]. Affected infants initially
present with feeding problems due to hypotonia and a poor suck, and the condition, in fact, represents
11% of children under the age of two years presenting with hypotonia [6]. From the age of two years
the clinical features are dominated by increasing weight gain, hyperphagia, and an insatiable appetite.
Other features include short stature, learning difficulties, dysmorphic facial features, low lean body
mass, hypogonadism, and sleep and behavioural disturbance [2,7]. The endocrine features of PWS are
well recognised and can include Growth Hormone Deficiency (GHD) or insufficiency, cryptorchidism
and hypogonadism, hypothyroidism, impaired glucose tolerance and diabetes mellitus [2]. Short term
treatment with recombinant growth hormone (GH) for children with PWS was first reported in 1987
and PWS has since become a licensed indication for its use [8].
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A less well studied aspect of PWS is the occurrence of adrenal insufficiency (AI). AI is the impaired
production of cortisol or action of ACTH, including unresponsiveness of the adrenals to ACTH [9].
Although AI was not included in the original descriptions of PWS, more recent studies have proposed
it as a possible additional feature.
To determine the importance of AI in patients with PWS, we performed a literature search with
Pubmed and Google Scholar using the terms “Prader Willi syndrome” and “adrenal insufficiency”
(AI), with the aim to consider current literature regarding the frequency and significance of adrenal
insufficiency in patients with PWS.
2. Why Could AI Be an Issue in PWS?
Studies have demonstrated that PWS is associated with a high rate of sudden unexpected death
at 3% [3,10], although these have been limited by their small sample size. As GH therapy has been
introduced in recent years, there have been some concerns that there could be an association between
GH therapy and sudden unexplained death in PWS. Nagai et al. [11], therefore, performed a post
mortem study on 13 patients who had not received GH therapy and seven who had. They found that
cause of death tended to correlate with age and stage of development rather than with GH treatment.
Young infants (0–1 year) typically died of milk aspiration secondary to hypothalamic dysregulation
of respiratory function. Young children and adolescents (1–19 years) died from complications of
respiratory infections, while young adults (ě20 years) died from the complications of obesity and
diabetes mellitus [11]. Tauber et al. [12] undertook a similar study, but had a larger cohort of 64 patients.
Again, respiratory disorders were the most common cause of death (COD) (61%) and GH therapy had
no correlation with increased death rate [12]. Table 1 summarises papers which report the cause of
death in patients with PWS.
Table 1. Cause of death in patients with PWS-summary of reports.
Author(s) Patients Method Results: Cause of Death
Schrander-Stumpel et al.,
2004 [13]
27 PWS patients who died
(age range birth–8 years)
Case reports
reviewed after death
Four cases of early morning sudden
unexplained death in context of
infectious symptoms
Stevenson et al., 2004 [14]
Eight patients with PWS
who died, ages
5 months–42 years
Case reports
reviewed after death
Three patients had hypoplastic adrenal
glands at time of postmortem
Van Vliet et al., 2004 [15] 1 PWS patient who diedaged four years
Case report reviewed
after death
Likely sleep apnoea and tonsillar
hypertrophy resulting in sudden death
Vogels et al., 2004 [4]
78 patients with PWS
(mean age 26 (range
0–56 years))—seven died
Data collected from
genetic centers in
Flanders
Sudden respiratory infections with a
high temperature most common. 1/7
(14%) patient died of sudden
collapse—cause unknown
Nagai et al., 2005 [11]
13 PWS patients who had
received GH therapy and
seven who had not
Post mortem study
Dependent on age group; young
infants (milk aspiration due
dysregulation of respiratory function).
Young children (complications of
respiratory infections). Teenagers and
young adults (complications of obesity
and diabetes)
Tauber et al., 2008 [12]
64 patients (age range 1
day–19 years), 28 on
GH therapy
Study of
post mortem reports
Respiratory causes in 24 (63%)
including infection and obstruction
secondary to tonsillar hypertrophy.
Sudden death of unknown cause in
11 (29%)
While the above studies establish a common primary cause of death, they do not fully explore
any underlying abnormality which could cause PWS children to be more susceptible to these
life-threatening respiratory infections. One possible explanation is an inability to mount an effective
Diseases 2016, 4, 5 3 of 7
cortisol response [10,14]. This was suggested after a post mortem study on eight individuals with PWS
(four infants aged 5–19 months, two toddlers aged 3.5 years, and two adults aged 29 and 43 years) [14].
Four of these individuals had an autopsy that recorded adrenal weight and of these three had well
below average adrenal weight for body length. This theorises that there could be an unrecognised
peripheral adrenal insufficiency in PWS children perhaps contributing to their deaths [14]. A larger
cohort of patients for further studies would be needed, however, to confirm this association.
To further investigate this hypothesis, one study used 3D MRI to review the pituitary gland while
simultaneously measuring basal pituitary hormonal levels in patients with PWS [16]. This found a
high prevalence of morphological pituitary abnormalities, such as hypoplasia and universal anterior
hormone deficiencies in PWS subjects. Although they did not measure ACTH specifically, if other
anterior hormones were deficient it is possible that ACTH would be too, although the authors recognise
that further studies are needed to explore this [16]. Interestingly this study had both a control group
and a group with early onset morbid obesity (EMO). The patients with EMO showed very similar
results to those with PWS, which could indicate that the aetiology of this pituitary deficiency may be,
in part, secondary to the obesity phenotype of PWS rather than congenital in nature, or may be just
normal variation.
In an attempt to explain the high sudden unexpected death rate in children with PWS,
studies [3,10] have postulated that PWS patients may be unable to mount an appropriate cortisol
response during stressful conditions, such as infection. Physiological stress, often induced by critical
illness, results in an acute and prolonged response of the HPA axis, causing an increase in plasma
cortisol and ACTH levels [17].
In 2008, de Lind van Wjingarden et al. [10] studied 25 randomly-selected PWS patients in
a paediatric intensive care unit (PICU), and used overnight single-dose metyrapone testing to
measure ACTH response alongside 11-deoxycortisol, cortisol and glucose levels. The median age was
9.7 (range 6.8–13.6) years. Diurnal salivary cortisol profiles were also assessed on an alternative day to
when the patients were receiving metyrapone. Central AI was confirmed if the ACTH response was
33 pmol/L at 0730 h. They found that 15 patients (60%) fulfilled the criteria of AI, however salivary
cortisol levels were normal in all patients, suggesting that AI only became apparent in induced stressful
conditions [10] and might offer an explanation for the high death rate from stress-related illnesses.
Following this study, two further studies were carried out to see if this level of AI was
replicated [18,19]. Corrias reviewed the adrenal responses of 84 PWS patients in a tertiary referral
centre. A total of 35 females and 49 males (age range 0.8–17.9 years) were enrolled in the study. The
adrenal response of these patients was assessed by measuring morning cortisol and ACTH dosage,
using a 1 µg synacthen test or low dose short synacthen test (LDSST), and an appropriate response
was considered to be more than 500 nmol/L. An LDSST supplies a lower dose of synthetic ACTH
than a standard short synacthen test (SST) where 250 micrograms of ACTH is administered. The
LDSST, therefore, represents the adrenal cortical response to ACTH administration, with studies
suggesting it may be the most reliable test for ACTH deficiency [20,21] as the LDSST may detect
adrenal insufficiency in those who had a normal SST [22], although this is a controversial area as there
is no clear evidence that one test is superior to the other. On the low dose synacthen stimulation test
12 patients had unsatisfactory cortisol responses (14.3%) with reduced basal (169.4 ˘ 83.3 nmol/L) and
stimulated (428.1˘ 69.6 nmol/L) cortisol levels [18]. These patients were retested using a standard dose
250 µg synacthen test which confirmed AI in four patients (4.8%). This result agreed with the study by
de Lind van Wjingarden et al. that AI is present in some PWS children. However, the statistics showed
it was less prevalent than previously reported [10].
A similar study was conducted as a follow up to the de Lind van Wjingarden paper by
Nyunt et al. [19]. This group used a low dose synacthen test (LDSST) (1 µg) to screen for AI in
41 PWS children (mean age 7.68 (˘5.23)) years, and measured ACTH and cortisol levels. This study,
however, provided contradictory evidence, as all children demonstrated a normal cortisol response of
ě500 nmol/L [19].
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Further contradictory evidence was provided in a study by Farholt et al. Their cohort consisted of
57 participants, 18 under the age of 17 and 39 adults (total median age 22; age range 0.6–48) and, of
this cohort, none showed any HPA dysfunction in response to a standard high dose synacthen test or
insulin tolerance test. From this we could conclude that not only is this condition rare but perhaps a
paediatric issue [23].
Another study that used LDSST on 53 PWS adults to determine the presence of AI [23]
showed that eight participants (15.1%) had an insufficient cortisol response, with a peak cortisol of
<500 nmol/L. These subjects were retested with a high dose short synacthen test (HDSST) and, of the
eight, four (7.5%) had suboptimal responses [24].
The above studies are summarised in Table 2. There is no obvious explanation for the differing
results, however the authors have suggested that perhaps the differing test methods or cut off levels
could be responsible. Measurement of cortisol using different assays itself has also changed over time
with lowering of acceptable cortisol thresholds. There is no current gold standard in terms of the type
of test used for AI in PWS or the frequency of monitoring required. To truly understand the prevalence
of AI in PWS children, further studies must be done.
Table 2. Summary of studies of adrenal insufficiency in PWS.
Author(s) Patient Group Method Level ConsideredSufficient Results
Grugni et al., 2013 [24] 53 PWS adults
Low dose short
synacthen test.
Deficient patients
retested with high
dose short synacthen
test
Peak cortisol response
>500 nmol/L
After LDSST eight
(15.1%) had a PCR of
<500 nmol/L. On
retesting 4 showed
persistent suboptimal
response (7.5%)
Corrias et al., 2012 [18]
84 PWS children
(35 females and
49 males aged
0.8–17.9 years).
Low-dose
tetracosactrin test
1 µg and standard
dose tetracosactrin
test (250 µg) in
second round of
testing
Peak cortisol response
>500 nmol/L
12 patients (14.3%)
had AI according to
LDSST but when
retested with SDSST
only 4 (4.8%) were
confirmed AI
Nyunt et al., 2010 [19]
Randomly selected
41 PWS children
(mean age 7.68
(˘5.23) years)
Low dose synacthen
test (1 µg)
Peak cortisol response
>500 nmol/L
All children had a
30 min cortisol
>500 nmol/L
De Lind van
Wijngaarden
et al., 2008 [10]
25 randomly selected
PICU patients,
median age 9.7
(6.8–13.6 years)
Overnight single dose
(30 mg/kg)
metyrapone test
ACTH >33 pmol/L at
0730 h
Fifteen patients (60%)
had an insufficient
ACTH response
Farholt et al., 2011 [23]
57 patients with PWS
(mean age 22 years,
range 0.5–48 years)
Standard high dose
synacthen test or
insulin tolerance test
Peak cortisol
response>500
nmol/L. Rise in
cortisol by
250nmol/L
All patients had a
normal response to
synacthen testing
3. The Effects of GH on AI in PWS
Adrenal insufficiency could also be iatrogenic in origin. Disruption of the HPA axis and growth
hormone deficiency in PWS have been well documented with growth hormone therapy now in
widespread use [25,26]. The AACE (American Association of Clinical Endocrinologists) guidelines
for the use of GH therapy remind clinicians that GH can inhibit the enzyme 11 β-hydroxysteroid
dehydrogenase type 1 causing a shift in cortisol metabolism to favour cortisone production and,
therefore, reduce global cortisol levels [27,28]. This may not have any clinical effect on most patients
but it may unmask central hypothyroidism and hypoadrenalism. [29]. They recommend, therefore, that
patients who become hypoadrenal on initiation of therapy should receive glucocorticoid replacement.
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Finally, it is known that GHD is associated with the development of other pituitary hormone
deficiencies, including ACTH deficiency [30]. Surveillance for this is therefore recommended in cases
of isolated GHD or cases with multiple pituitary hormone defects [30], suggesting that this should
also be considered in patients with PWS.
4. Summary and Conclusions
Prader Willi syndrome is a congenital condition with a complex phenotype. It is clear that some
association between PWS and AI appears to exist, although this may be a predominantly paediatric
issue, as Farholt et al. demonstrated in 39 adult PWS subjects with a normal HPA axis [23]. Which
PWS patients are most at risk of this remains unclear, as does how best to test for this worrying
phenomenon. Having reviewed the current literature, we would advise that there is enough of a
reported association for clinicians to have a low threshold for testing PWS for adrenal insufficiency
and to treat according to the results and clinical picture. If there is clinical suspicion, it would be safer
to treat with hydrocortisone, even if only during intercurrent illnesses or if severely unwell. Further
research is required, however, to confirm what the mechanism behind AI is and which patients are
most at risk and how best to monitor for this.
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